Biomerica (BMRA)
(Delayed Data from NSDQ)
$0.58 USD
-0.05 (-7.84%)
Updated May 31, 2024 04:00 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Biomerica, Inc. [BMRA]
Reports for Purchase
Showing records 21 - 40 ( 44 total )
Company: Biomerica, Inc.
Industry: Medical - Drugs
Reports 2Q16 Results; Maintaining BUY Rating and $2.85 PT
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Reports 4Q15 Results; Maintaining BUY Rating and $2.85 PT
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Uneventful 3Q15 Results But The Company Establishes Advisory Board For New IBS Product
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Reports 1Q15 Results; Maintaining BUY Rating and $2.85 PT
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Reports 3Q14 Results; Maintaining BUY Rating and $2.85 PT
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A
Company: Biomerica, Inc.
Industry: Medical - Drugs
Company: Biomerica, Inc.
Industry: Medical - Drugs
Detecting Strong Upside Potential; Initiating Coverage With a BUY Rating and $2.85 PT
Provider: Merriman Curhan Ford & Co.
Analyst: D SILVA A